Evidence map›Paper›PMID 30419649›Full record

ArticleClinical and molecular hepatology2019

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.

David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. [Research progress of antiviral treatment for patients with chronic hepatitis B combined with metabolic fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

David Sooik KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Mi Young JeonDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Hye Won LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Beom Kyung KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jun Yong ParkDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Do Young KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Sang Hoon AhnDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kwang-Hyub HanDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Seung Up KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yonsei University · KRSeverance Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy.

methodsA total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited.

resultsOf the total study population, 146 (43.7%) patients had HS (CAP > 238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA<12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P=0.022).

conclusionCAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.

Indexed as

AdultAntiviral AgentsFatty LiverFemaleGuanineHepatitis B, ChronicHepatitis B e AntigensHumansMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsSustained Virologic ResponseTenofovirTreatment OutcomeAntiviral AgentsentecavirGuanineHepatitis B e AntigensTenofovirAntiviral agentFatty liverHepatitis B, Chronic

Identifiers

PMID30419649
PMCPMC6759433
OpenAlexW2900700829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.